Perceive Pharma Overview
- Year Founded
-
2023
- Status
-
Private
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$15M
- Investors
-
7
Perceive Pharma General Information
Description
Developer of small molecule neuroprotective therapeutics designed for targeting glaucoma and other ophthalmic diseases. The company's platform leverages retina cell screening to identify neuroprotective biological pathways, enabling healthcare professionals to offer innovative treatments for vision-related neurodegenerative conditions, improving patient outcomes in the ophthalmic space.
Contact Information
Corporate Office
- San Francisco, CA
- United States
Corporate Office
- San Francisco, CA
- United States
Perceive Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Early Stage VC (Series A) | 18-Feb-2025 | $15M | Completed | Startup | ||
| 3. Accelerator/Incubator | Completed | Startup | ||||
| 2. Seed Round | $4.5M | $4.5M | Completed | Startup | ||
| 1. Spin-Off | Completed | Startup |
Perceive Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Seed-5 | ||||||||
| Seed-4 | ||||||||
| Seed-3 | ||||||||
| Seed-2 | 2,448,106 | $0.000100 | 8% | $0.31 | $0.31 | 1x | $0.31 | 6.37% |
| Seed-1 | 2,631,565 | $0.000100 | 8% | $0.2 | $0.2 | 1x | $0.2 | 6.85% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Perceive Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Perceive Pharma Patents
Perceive Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025096944-A1 | Systems for sustained intraocular delivery of dual leucine zipper kinase and leucine zipper kinase inhibitors | Inactive | 03-Nov-2023 |
Perceive Pharma Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Braidwell | Hedge Fund | Minority | ||
| Catalio Capital Management | Venture Capital | Minority | ||
| Deerfield Management | Venture Capital | Minority | ||
| GV | Corporate Venture Capital | Minority | ||
| Johnson & Johnson JJDC | Corporate Venture Capital | Minority |
Perceive Pharma FAQs
-
When was Perceive Pharma founded?
Perceive Pharma was founded in 2023.
-
Where is Perceive Pharma headquartered?
Perceive Pharma is headquartered in San Francisco, CA.
-
What industry is Perceive Pharma in?
Perceive Pharma’s primary industry is Drug Discovery.
-
Is Perceive Pharma a private or public company?
Perceive Pharma is a Private company.
-
What is the current valuation of Perceive Pharma?
The current valuation of Perceive Pharma is .
-
What is Perceive Pharma’s current revenue?
The current revenue for Perceive Pharma is .
-
How much funding has Perceive Pharma raised over time?
Perceive Pharma has raised $19.5M.
-
Who are Perceive Pharma’s investors?
Braidwell, Catalio Capital Management, Deerfield Management, GV, and Johnson & Johnson JJDC are 5 of 7 investors who have invested in Perceive Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
